The US Food and Drug Administration (FDA) has chosen IBM, Merck, KPMG and...
FDA chooses IBM, KMPG, Merck and Walmart for pharma blockchain pilot
The US Food and Drug Administration (FDA) has chosen IBM, Merck, KPMG and Walmart to support its latest Drug Supply Chain Security Act (DSCSA) pilot programme, which focuses on blockchain interoperability.
Lonafarnib, a hope for progeria treatment
Lonafarnib has emerged as a potential treatment for progeria and progeroid laminopathies, an ultra-rare condition for which no approved treatment exists.
Having successfully demonstrated survival benefits in progeria patients, lonafarnib is improving the hope for the patients, who generally succumb to death at an early age of 14 years.
The drug currently has orphan drug, breakthrough therapy, as well as rare paediatric disease (RPD) designations from the US Food and Drug Administration (FDA).
Insys to pay $225m to settle opioid painkiller marketing probe in US
The US Department of Justice (DoJ) has alleged that Insys Therapeutics took part in a type of negotiated bribery and carried out illegal marketing for its opioid painkiller Subsys.
ILC Dover Manufacturing Facility
In May 2019, ILC Dover opened a manufacturing facility in Ireland to produce the company’s pharmaceutical and biopharmaceutical product lines. The plant is designed to strengthen the company's single-use powder handling solutions business.
May’s top news stories
Takeda Pharmaceutical has signed an agreement to sell its Xiidra 5% drug to Novartis for a total consideration of up to $5.3bn, and The UK’s NHS has signed a managed access agreement to fund Biogen’s Spinraza for a limited time to ascertain its effectiveness as a treatment for 5q spinal muscular atrophy (SMA). Pharmaceutical-technology.com wraps up key headlines from May 2019.
How simplification and behaviour change can optimise a pharmaceutical operation
A focused simplification strategy will offer game-changing results in pharma operations. Regulation is inherently complex, and the bar seems to get higher with each passing year or with the issuing of new guidance. Staying current is not easy and managing the inherent, ever-growing complexity is can be a serious challenge.
WHO adopts resolution on drug pricing transparency
Member countries of the World Health Organization (WHO) have agreed to support pricing transparency for medicines, vaccines and other health products.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.